Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

First Posted Date: 2023-08-28

Last Posted Date: 2024-08-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 54

Registration Number: NCT06013423

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Phase 1

Recruiting

Conditions: Non Hodgkin's Lymphoma

Interventions: Biological: TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-08-28

Last Posted Date: 2023-09-11

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT06014073

Locations: 🇨🇳
EdiGene Inc, Beijing, China
🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, China
🇨🇳
School of Life Sciences, Peking University, Beijing, China

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Phase 1

Not yet recruiting

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: HY004
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2023-08-24

Last Posted Date: 2024-03-08

Lead Sponsor: Juventas Cell Therapy Ltd.

Target Recruit Count: 50

Registration Number: NCT06009107

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

Phase 1

Recruiting

Conditions: B-cell Lymphoma

Interventions: Biological: CAR20(NAP)-T
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-08-21

Last Posted Date: 2024-05-09

Lead Sponsor: Uppsala University

Target Recruit Count: 18

Registration Number: NCT06002659

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Phase 2

Recruiting

Conditions: Adolescent
Neoplasms
Child

Interventions: Drug: Ramucirumab
Drug: Cyclophosphamide
Drug: Abemaciclib
Drug: Irinotecan
Drug: Docetaxel
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Temozolomide

First Posted Date: 2023-08-21

Last Posted Date: 2024-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 105

Registration Number: NCT05999994

Locations: 🇧🇪
UCL- Saint Luc, Bruxelles, Belgium
🇫🇷
Institut Curie, Paris, France
🇳🇱
Prinses Maxima Centrum, Utrecht, Netherlands

and more 63 locations

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-27

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 190

Registration Number: NCT06001385

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 21 locations

Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Phase 1

Withdrawn

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Radiation: TLI
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT06003179

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Letetresgene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-08-15

Last Posted Date: 2024-10-22

Lead Sponsor: Adaptimmune

Target Recruit Count: 7

Registration Number: NCT05993299

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States

and more 35 locations